Fracture healing compound enters trials:
This article was originally published in Clinica
Orthopaedic device manufacturer OrthoLogic has begun enrolling patients in a trial of a compound for speeding up fracture healing. The double-blind Phase I/II study of 90 patients will evaluate the safety and preliminary efficacy of Chrysalin, a synthetic peptide, which is injected at the fracture site. Tempe, Arizona-based OrthoLogic has acquired an equity stake in start-up biotech firm Chrysalis BioTechnology, based in Galveston, Texas.